TA1 vs Thymalin
A side-by-side research comparison of TA1 and Thymalin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Thymalin |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Thymalin (Thymus Extract Peptide) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Contains bioactive thymic peptides that regulate T-lymphocyte differentiation, restore T-helper/T-suppressor ratios, and enhance phagocyte activity and interferon production. |
| Molecular weight | 3108.3 Da | ~1000-5000 Da (complex mixture) |
| Half-life | ~2-3 hours | ~4-6 hours |
| Bioavailability | ~85% subcutaneous | ~80% intramuscular |
| Typical dose | 1.6 mg | 5-10 mg |
| Frequency | 2x per week | Daily for 5-10 days |
| Route | Subcutaneous injection | Intramuscular injection |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Thymalin reported benefits
- Immune reconstitution
- T-cell ratio normalization
- Interferon production
- Anti-tumor immunity support
Related comparisons
Research and educational reference only. Not medical advice.